Most importantly, we demonstrate that the TGFβ-EMT signature, in both the microarray and NanoString format, can predict not only overall survival (OS), but also metastasis-free survival (MFS) in patients with NSCLC. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.